Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower.
Left:
||||
Year-over-year research & development expense growth
Latest
14.78%
↓ 13% below average
Average (9y)
17.08%
Historical baseline
Range
High:66.77%
Low:-12.96%
CAGR
-1.2%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | 14.78% |
| 2023 | 19.09% |
| 2022 | -12.96% |
| 2021 | 66.77% |
| 2020 | 4.27% |
| 2019 | 23.87% |
| 2018 | 6.93% |
| 2017 | 26.43% |
| 2016 | 5.17% |
| 2015 | 16.44% |